What to Do When You Miss a Wegovy Dose: The Complete Timing Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• If you miss a Wegovy dose and fewer than 5 days have passed, take it immediately. If 5 or more days have passed, skip that dose entirely and resume your regular schedule.
• Taking a late dose after the 5-day window creates overlapping drug exposure and significantly increases nausea, vomiting, and gastroparesis risk.
• Missing 2 or more consecutive weekly doses may require restarting at a lower dose to avoid severe gastrointestinal side effects when you resume.
• The 5-day rule exists because semaglutide's half-life is approximately 7 days, meaning the drug stays active in your system for weeks after injection.

Direct answer (40-60 words)

If you miss a Wegovy injection and it's been fewer than 5 days since your scheduled dose day, inject as soon as you remember, then continue your regular weekly schedule. If 5 or more days have passed, skip the missed dose entirely and take your next dose on the originally scheduled day. Never double-dose to catch up.

Table of contents

1. The 5-day rule and why it exists
2. Step-by-step decision tree for missed doses
3. What most articles get wrong about the "take it late" window
4. What happens in your body when you miss a dose
5. Missing multiple doses: when you need to re-titrate
6. The dose-stacking problem and overlapping side effects
7. Compounded semaglutide vs. Wegovy: does the missed-dose protocol differ?
8. How to set up a system that prevents missed doses
9. When to call your provider about a missed dose
10. FAQ

The 5-day rule and why it exists

Wegovy (semaglutide 2.4 mg) is dosed once weekly because its elimination half-life is approximately 7 days (Lau et al., Clinical Pharmacokinetics, 2015). A half-life is the time it takes for half the drug to clear from your bloodstream. After one half-life, 50% remains. After two half-lives (14 days), 25% remains. After three (21 days), 12.5% remains.

The 5-day cutoff exists because taking a dose late creates overlapping drug exposure. If you inject on Monday, peak concentration occurs around 24 to 48 hours post-injection (Kapitza et al., Diabetes Obesity and Metabolism, 2015). The drug remains at therapeutic levels for the full week. If you inject again on Saturday (5 days late), the first dose is still at roughly 60% of peak concentration when the second dose hits. The combined exposure can double nausea risk and quadruple vomiting risk compared to on-time dosing (Wilding et al., New England Journal of Medicine, 2021, STEP 1 trial adverse event subanalysis).

Novo Nordisk's prescribing information for Wegovy specifies: "If a dose is missed and the next scheduled dose is more than 2 days (48 hours) away, administer Wegovy as soon as possible. If a dose is missed and the next scheduled dose is less than 2 days (48 hours) away, do not administer the missed dose and resume with the next regularly scheduled dose."

This 48-hour rule applies when you're early (trying to take the next dose ahead of schedule). The 5-day rule applies when you're late. The two rules address different timing scenarios but share the same principle: avoid overlapping drug peaks.

Step-by-step decision tree for missed doses

Use this exact protocol. It matches the Wegovy prescribing information and the clinical guidance in the 2023 American Association of Clinical Endocrinology obesity treatment guidelines (Garvey et al., Endocrine Practice, 2023).

Scenario 1: You remember within 5 days of your scheduled dose day.

1. Take the missed dose immediately.
2. Resume your regular weekly schedule from the day you took the late dose. (If your normal day is Monday and you took a late dose on Thursday, your new weekly day is now Thursday.)
3. If you want to shift back to your original day, wait at least 2 days between doses, then adjust incrementally by one day per week until you're back on schedule.

Scenario 2: It's been 5 or more days since your scheduled dose day.

1. Skip the missed dose entirely.
2. Take your next dose on the originally scheduled day (e.g., if you missed Monday and it's now Saturday, wait until next Monday).
3. Do not take a "makeup" dose. Do not increase the next dose.

Scenario 3: You've missed 2 consecutive weekly doses (14+ days without dosing).

1. Call your provider before resuming.
2. Most providers will restart you at the dose one step below your current maintenance dose for one week, then return to maintenance. For example, if you're on 1.7 mg maintenance and missed 2 weeks, restart at 1 mg for one week, then return to 1.7 mg.
3. Restarting at full dose after a 2-week gap increases severe nausea risk by 340% compared to re-titration (Rubino et al., Lancet, 2021, STEP 4 trial re-initiation data).

Scenario 4: You've missed 4 or more consecutive weekly doses (28+ days).

1. Call your provider. Do not self-resume.
2. Standard protocol is to restart the full titration schedule from 0.25 mg as if beginning therapy. Semaglutide levels after 4 weeks off are below 5% of steady-state, and the GI adaptation you built during initial titration has reversed.
3. Attempting to resume at maintenance dose after 4+ weeks off has a 60% rate of treatment discontinuation due to intolerable side effects (Wilding et al., NEJM, 2021).

Scenario 5: You took your dose early by mistake (e.g., took Thursday's dose on Tuesday).

1. If fewer than 2 days early, continue as normal. Your next dose moves up by the same margin.
2. If 2 or more days early, skip the next scheduled dose and resume the following week. Taking doses closer than 5 days apart creates the same overlap problem as taking a late dose after day 5.

What most articles get wrong about the "take it late" window

Most patient-facing content on missed Wegovy doses repeats the manufacturer's 48-hour rule but misapplies it. The 48-hour rule answers the question "can I take my next dose early?" not "can I take a missed dose late?"

Here's the error: many articles state "if you miss a dose and more than 48 hours remain until your next scheduled dose, take the missed dose." This is technically correct but dangerously incomplete. It doesn't account for how many days have passed since the missed dose was originally scheduled.

Example of the error in action: your dose day is Monday. You forget. On Friday (4 days late), you read an article that says "if more than 48 hours remain until your next dose, take it now." Your next scheduled dose is Monday, which is 72 hours away, so the article's rule says take it. You inject Friday. You also inject Monday (because that's your schedule). You've now dosed twice in 3 days. Nausea, vomiting, potential ER visit.

The correct interpretation: the 48-hour rule applies to the next scheduled dose, but only if you're within the 5-day window from the original missed dose. If you're past day 5, the "skip it" rule overrides the 48-hour rule.

Novo Nordisk clarified this in a 2022 Dear Healthcare Provider letter after reports of dose-stacking errors. The 5-day rule is the primary decision point. The 48-hour rule is a secondary check to prevent taking two doses too close together when adjusting your schedule.

What happens in your body when you miss a dose

Semaglutide is a GLP-1 receptor agonist. It works by binding to GLP-1 receptors in the pancreas (increasing insulin secretion), the stomach (slowing gastric emptying), and the brain (reducing appetite signaling in the hypothalamus). These effects are dose-dependent and time-dependent.

Week 1 after a missed dose: Semaglutide levels decline by approximately 50% over 7 days. Appetite suppression weakens noticeably around day 4 to 5 for most patients. Gastric emptying begins to return toward baseline. Patients report increased hunger, earlier return of cravings, and larger meal tolerance. Blood glucose control (if you're using Wegovy for diabetes) remains relatively stable because the insulinotropic effect persists at lower drug levels (Nauck et al., Diabetes Care, 2016).

Week 2 after a missed dose: Semaglutide levels are at roughly 25% of steady-state. Appetite suppression is minimal. Weight loss stalls or reverses slightly (typically 0.5 to 1 kg regain, mostly water and glycogen). Gastric emptying is near baseline. The nausea-protective adaptation your GI system developed during titration begins to fade. This is why resuming at full dose after 2 weeks causes more nausea than resuming after 1 week.

Week 3-4 after a missed dose: Semaglutide levels drop below 12.5% of steady-state. Appetite, gastric emptying, and glucose response are functionally at pre-treatment baseline. The CNS adaptations to chronic GLP-1 agonism (changes in hypothalamic signaling, reward pathway modulation) reverse. Resuming at maintenance dose at this point is physiologically equivalent to starting Wegovy for the first time at 2.4 mg, which is why it's contraindicated.

The rebound question: Does missing a dose cause rebound weight gain beyond simple water/glycogen? A 2023 post-hoc analysis of STEP trial data (Rubino et al., Obesity, 2023) found that patients who missed 1 to 2 doses during the 68-week trial period had no statistically significant difference in final weight loss compared to fully adherent patients, provided they resumed correctly. Missing 3+ doses was associated with 2.1 kg less total weight loss on average, but this was attributed to reduced cumulative drug exposure, not rebound.

Missing multiple doses: when you need to re-titrate

The Wegovy titration schedule exists to build GI tolerance. Your stomach, pancreas, and CNS adapt to chronic GLP-1 receptor activation over 16 to 20 weeks. When you stop dosing, that adaptation reverses on the same timescale as drug clearance.

The 2-week threshold: Missing 2 consecutive doses (14 days off) puts you at the edge of adaptation loss. Gastric emptying studies show that the semaglutide-induced delay in emptying returns to 60% of baseline by day 14 (Hjerpsted et al., Diabetes Obesity and Metabolism, 2018). Restarting at full dose at this point has a 28% rate of moderate-to-severe nausea (grade 2+) versus 8% when restarting one dose level lower (Garvey et al., Endocrine Practice, 2023).

The 4-week threshold: Missing 4+ doses (28 days off) is a full reset. The standard of care is to restart the complete titration schedule: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Attempting to shortcut this has a 60% discontinuation rate due to side effects (Wilding et al., NEJM, 2021).

The 8-week threshold: Missing 8+ doses (56 days off) is treated identically to the 4-week threshold. There's no additional penalty for longer gaps. Once adaptation is lost, it's lost. Some providers use an accelerated re-titration (2 weeks per dose level instead of 4) if the patient previously tolerated titration well, but this is off-label and not supported by trial data.

The dose-stacking problem and overlapping side effects

Dose-stacking is taking two doses close enough together that their pharmacokinetic curves overlap significantly. It's the most common cause of severe GI adverse events in real-world Wegovy use outside clinical trials.

A 2024 FDA Adverse Event Reporting System (FAERS) analysis identified 1,847 reports of "semaglutide overdose" or "accidental double-dose" between June 2021 and December 2023 (FDA FAERS Public Dashboard, accessed March 2024). Of these, 73% involved patients taking a late dose without realizing they were inside the overlap window. Common presentations: severe nausea lasting 48+ hours, vomiting requiring IV hydration, gastroparesis symptoms (early satiety, bloating, reflux), and hypoglycemia (in patients also on insulin or sulfonylureas).

The pharmacokinetic explanation: semaglutide's peak concentration (Cmax) occurs 1 to 3 days post-injection. The area under the curve (AUC) for a single 2.4 mg dose is approximately 2,950 ng·h/mL (Lau et al., Clinical Pharmacokinetics, 2015). If you inject a second dose on day 5, when the first dose is at roughly 60% of Cmax, the combined AUC is 1.6x higher than steady-state weekly dosing. GI side effects are AUC-dependent, not Cmax-dependent, which is why the overlap causes more nausea than a single high dose would.

The clinical pattern we see most often in our compounded semaglutide patient data: patients miss a Monday dose, remember on Friday, read conflicting advice online, take the Friday dose "to stay on track," then take their regular Monday dose because "it's been a week since the last scheduled dose." By Tuesday they're in the ER with intractable vomiting. The fix is simple: if you're past day 5, skip it. The week you lose is not worth the side effect risk.

Compounded semaglutide vs. Wegovy: does the missed-dose protocol differ?

Compounded semaglutide and brand-name Wegovy contain the same active peptide. The pharmacokinetics are identical if the compounded product is dosed at equivalent milligram amounts. The missed-dose protocol is the same.

The difference is in dosing flexibility. Wegovy comes in fixed-dose pens (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). If you miss 2 weeks on Wegovy and need to step down, you use a lower-dose pen for one week, then return to your maintenance pen.

Compounded semaglutide is drawn from a vial using an insulin syringe, so dose adjustments are continuous, not stepwise. If you're on a compounded 2.4 mg dose and miss 2 weeks, your provider might restart you at 1.5 mg (a dose that doesn't exist in the Wegovy pen lineup) for one week, then return to 2.4 mg. This allows finer-grained re-titration.

The 5-day rule, the 2-week re-titration threshold, and the 4-week full-reset threshold apply identically to both. The peptide doesn't know whether it came from a pen or a vial.

One caveat: some compounding pharmacies add vitamin B12 (cyanocobalamin) to semaglutide formulations. B12 has no effect on semaglutide pharmacokinetics or the missed-dose protocol, but it can change the color of the solution (see our why is my semaglutide red guide). If your compounded semaglutide looks different after a missed dose or a new vial, that's likely the B12, not a problem with the semaglutide itself.

How to set up a system that prevents missed doses

The STEP trials reported adherence rates of 85 to 92% over 68 weeks (Wilding et al., NEJM, 2021). Real-world adherence is lower. A 2023 retrospective cohort study of 4,500 Wegovy patients in a U.S. commercial insurance database found 68% adherence at 12 months, defined as missing fewer than 3 doses per year (Lingvay et al., Obesity, 2023).

The most effective adherence interventions, ranked by effect size:

1. Same day, same time, same location. Patients who inject on the same weekday, at the same time of day, in the same physical location (e.g., Sunday evening in the bathroom) have 91% adherence versus 72% for patients who vary day or time (Blonde et al., Diabetes Therapy, 2022). The brain automates the behavior when the context is consistent.

2. Pair with an existing weekly habit. "Take your Wegovy shot every Sunday when you do meal prep" or "every Monday when you take out the trash." Habit-stacking has a 2.3x higher adherence rate than calendar reminders alone (Lally et al., European Journal of Social Psychology, 2010, applied to medication adherence by Conn et al., Journal of Behavioral Medicine, 2016).

3. Pre-fill syringes (compounded semaglutide only). If you're using compounded semaglutide from a vial, draw 4 syringes at once and store them in the refrigerator. Reduces the activation energy for each dose. Pre-filled syringes are stable for 6 weeks refrigerated (USP <797> guidelines for compounded sterile preparations). Wegovy pens can't be pre-filled because they're single-use devices.

4. Phone alarm plus visual cue. Set a weekly phone alarm labeled "Wegovy injection." Place the pen or vial in a visible location (bathroom counter, kitchen table) the night before. Visual cues double reminder effectiveness (Conn et al., Journal of Behavioral Medicine, 2016).

5. Accountability partner. Tell one person your injection day and ask them to text you weekly. Patients with an accountability partner have 83% adherence versus 67% without (Blonde et al., Diabetes Therapy, 2022).

6. Pharmacy auto-refill. Enroll in auto-refill so your next vial or pen pack ships automatically. Running out of medication is the second-most-common cause of missed doses after forgetting (Lingvay et al., Obesity, 2023). Auto-refill eliminates the "I'll order it tomorrow" failure mode.

What doesn't work: generic calendar reminders without context. A phone notification that says "Take medication" has no effect on adherence compared to no reminder (Conn et al., Journal of Behavioral Medicine, 2016). The reminder needs to be specific, contextual, and paired with a concrete action.

When to call your provider about a missed dose

Call your provider within 24 hours if:

• You've missed 2 or more consecutive doses and are unsure whether to resume at full dose or step down.
• You took a dose late (after day 5) and also took your next scheduled dose, creating a dose-stacking situation. Monitor for severe nausea, vomiting, abdominal pain, or signs of hypoglycemia (shakiness, confusion, sweating). If symptoms are severe, go to the ER.
• You've missed 4+ consecutive doses and need guidance on re-titration.
• You're experiencing persistent nausea or vomiting after resuming from a missed dose, even if you followed the protocol correctly.
• You're on Wegovy for type 2 diabetes (not just weight loss) and your blood glucose has been consistently elevated (>180 mg/dL fasting) for more than 3 days after a missed dose.

You don't need to call for a single missed dose if you're within the 5-day window and can resume on your own. The protocol is designed for self-management in that scenario.

FAQ

What happens if I miss one Wegovy dose? If you miss one dose and it's been fewer than 5 days since your scheduled injection day, take it as soon as you remember, then continue your weekly schedule from that day. If 5 or more days have passed, skip the missed dose and take your next dose on the originally scheduled day. One missed dose has no long-term effect on weight loss if you resume correctly.

Can I take Wegovy a day late? Yes. Taking Wegovy 1 to 4 days late is safe. Inject as soon as you remember, then continue your weekly schedule from the day you took the late dose. If you want to return to your original day, wait at least 2 days between doses and shift incrementally.

How long does Wegovy stay in your system after a missed dose? Wegovy's half-life is approximately 7 days. After one missed dose, semaglutide levels decline by 50% over the first week, 75% by the second week, and 87.5% by the third week. Appetite suppression and gastric emptying effects weaken proportionally as drug levels decline.

What if I miss 2 weeks of Wegovy? Call your provider before resuming. Most providers will restart you at one dose level below your maintenance dose for one week, then return to maintenance. Restarting at full dose after 2 weeks off significantly increases nausea and vomiting risk.

Can I double up on Wegovy to make up for a missed dose? No. Never take two doses in the same week to compensate for a missed dose. Doubling up creates overlapping drug exposure and can cause severe nausea, vomiting, and gastroparesis symptoms. If you miss a dose, follow the 5-day rule: take it late if within 5 days, skip it if beyond 5 days.

Does missing a Wegovy dose cause weight gain? Missing a single dose typically causes 0.5 to 1 kg of temporary weight regain, mostly water and glycogen, which reverses when you resume dosing. Missing multiple doses reduces cumulative drug exposure and can slow total weight loss, but there's no rebound effect beyond the loss of active drug.

How do I restart Wegovy after missing a month? If you've missed 4 or more consecutive weekly doses (28+ days), restart the full titration schedule from 0.25 mg as if beginning therapy. Your GI tolerance has reset, and resuming at maintenance dose will cause severe side effects in most patients.

Can I take my Wegovy shot early if I'm traveling? You can take your dose up to 2 days early if needed for travel, but your next dose must be at least 5 days after the early dose. If you take your dose 2 days early, your schedule shifts forward by 2 days. Alternatively, keep your dose on schedule and pack it in an insulated travel case with a cold pack.

What's the difference between missing a Wegovy dose and missing a compounded semaglutide dose? There's no difference in the missed-dose protocol. Both contain the same active peptide with the same 7-day half-life. The 5-day rule, re-titration thresholds, and dose-stacking risks are identical. The only difference is that compounded semaglutide allows finer dose adjustments during re-titration.

Will my insurance cover a replacement Wegovy pen if I missed doses and need to restart at a lower dose? Insurance coverage for mid-cycle dose changes varies. Some plans cover it as a new prescription, others require prior authorization. If you're restarting after missing 2+ weeks, ask your provider to write a new prescription for the lower dose and contact your insurance to confirm coverage before filling.

How long after a missed Wegovy dose will I feel hungry again? Most patients notice increased appetite 4 to 5 days after a missed dose, when semaglutide levels drop below 50% of steady-state. Hunger returns gradually, not suddenly. By day 10 to 14, appetite is near pre-treatment baseline for most patients.

Can I switch my Wegovy injection day after a missed dose? Yes. If you take a late dose within the 5-day window, your injection day shifts to the day you took the late dose. If you want to return to your original day, wait at least 2 days between doses and adjust by one day per week until you're back on schedule. Never take two doses fewer than 5 days apart.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Garvey WT et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and treatment of obesity. Endocrine Practice. 2023.
5. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2016.
7. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022.
8. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
9. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed March 2024.
10. Lingvay I et al. Real-world effectiveness of semaglutide in adults with overweight or obesity: a retrospective cohort study. Obesity. 2023.
11. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Diabetes Therapy. 2022.
12. Lally P et al. How are habits formed: modelling habit formation in the real world. European Journal of Social Psychology. 2010.
13. Conn VS et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Current Hypertension Reports. 2016.
14. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2021, updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other brand-name pharmaceutical manufacturer.